KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Income from Continuing Operations (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Income from Continuing Operations for 15 consecutive years, with 21986000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 63.52% year-over-year to 21986000.0, compared with a TTM value of 50261000.0 through Dec 2025, up 84.32%, and an annual FY2025 reading of 50261000.0, up 84.32% over the prior year.
  • Income from Continuing Operations was 21986000.0 for Q4 2025 at Travere Therapeutics, down from 25706000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 25706000.0 in Q3 2025 and bottomed at 135958000.0 in Q1 2024.
  • Average Income from Continuing Operations over 5 years is 64799200.0, with a median of 74837500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 6766.71% in 2021, then surged 146.95% in 2025.
  • Year by year, Income from Continuing Operations stood at 88774000.0 in 2021, then grew by 3.53% to 85636000.0 in 2022, then dropped by 3.46% to 88596000.0 in 2023, then skyrocketed by 31.97% to 60268000.0 in 2024, then skyrocketed by 63.52% to 21986000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TVTX at 21986000.0 in Q4 2025, 25706000.0 in Q3 2025, and 12755000.0 in Q2 2025.